Quantum Materials Corp. (fka QTMM)

[drugmanrx]

Receivership the end or the path to a new beginning?

Receivership offers an insolvent company the opportunity to recover and resume business operations. Once the receiver has fulfilled their appointed role, the company can oftentimes be handed back to its directors and shareholders.

https://www.dottoreco.com/blog/what-is-the-difference-between-receivership-liquidation-19813

It would seem logical that a receiver would follow the path out lined by Amber as it would benefit all parties involved, if successful.

Hi and thank you for your inquiry,
The company and its staff are intensely focused on optimizing its rapid diagnostic test platform technologies. We have organized clinical trials for our covid, flu, RSV multi-test and anticipate these should begin early May 2023 with the goal of having this test available for the next flu season. Our pre-submission has already been submitted to the FDA and we believe this test will be processed under the EUA.
We are continuing to develop our long covid rapid test striving to have it ready for clinical trials before the end of 2023.

Our CFO and his staff re continuing to work to position the company to submit an S1 before the end of this year. In the meantime, our limited financial resources will continue to be largely focused on the commercialization of our products until such a time sustainable revenues are achieved.

Thank you again for your inquiry and your patience as we work to bring our disruptive technologies to market.

Amber

Amber e-mail validity backed by:

" Et al. Podesta.com representing Quantum Materials Corp. has filed their fourth quarter 2022 lobbying report entering 2023 still in the lobbying process."

https://projects.propublica.org/represent/lob.../301036564